Glenmark to market Tiotropium Bromide dry powder inhaler in Western Europe

Glenmark Pharmaceuticals Europe has entered into a strategic, exclusive licensing agreement for marketing generic Tiotropium Bromide dry powder inhaler, used in the treatment of chronic obstructive pulmonary disease, in Western Europe.

Glenmark Pharmaceuticals EVP & Business Head of Europe and Latin America Achin Gupta said, respiratory is a core area of focus for Glenmark and this deal shows our commitment to increase product offerings within this segment.

"There is significant opportunity in the inhalers market and we believe that this deal will give further impetus to Glenmark’s growth in Europe," he added. This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler, the company said.

 --------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.